ClinicalTrials.gg
Drug

TACI receptor-IgG Fc fragment fusion protein clinical trials

Also written Atacicept and VT-001.

Its developmentBy Merck KGaA, Darmstadt, Germany and Vera Therapeutics, step by step18 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
18
open now
2
in phase 3
4
first study started
2006

How each study uses TACI receptor-IgG Fc fragment fusion protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the TACI receptor-IgG Fc fragment fusion protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
7 Jul 2026 · TRUTAKNA · BLA 761486 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

VT-001
3

Other names

Atacicept
12
Atacicept 150 mg
5
Atacicept 75 mg
4
Atacicept 25 mg
2

Studies by the year they started

18 studies that test it; most in 2008 (4)

Studies that test TACI receptor-IgG Fc fragment fusion protein, by start year
YearStudies
20061
20072
20084
20091
20111
20121
20131
20141
20171
20221
20231
20241
20252

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
15
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 18 · Other 0

EMD Serono (11) · Vera Therapeutics, Inc. (5) · Merck KGaA, Darmstadt, Germany (1) · EMD Serono Research & Development Institute, Inc. (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test TACI receptor-IgG Fc fragment fusion protein.

Studies

Open first, then newest update. How each study uses TACI receptor-IgG Fc fragment fusion protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Codes

What other systems call TACI receptor-IgG Fc fragment fusion protein · ClinicalTrials.gg INT005189

  • MeSH (NLM) C524618TACI receptor-IgG Fc fragment fusion proteinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) K3D9A0ICQ3ATACICEPTConfirmed FDA, NLM

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.